EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy

Jean-Frédéric Colombel, Tadakazu Hisamatsu, Raja Atreya, Francesca Bresso, Lena Thin, Remo Panaccione, Rogério Serafim Parra, Sharanya Ford, Valencia P Remple, Ana Paula Lacerda, Samuel I Anyanwu, Madhuja Mallick und 2 weitere

Clinical Gastroenterology and Hepatology · 2024-08 · 22 (8) · 1668-1677

DOI: 10.1016/j.cgh.2024.02.027 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-08. Verfasst von Jean-Frédéric Colombel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic addre…. Hauptthemen laut MEDLINE: Crohn Disease, Heterocyclic Compounds, 3-Ring, Induction Chemotherapy. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseHeterocyclic Compounds, 3-RingInduction ChemotherapyAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodPlacebosTreatment Outcome

Stichwörter der Autor:innen

Crohn’s DiseaseRapid Symptom ReliefUpadacitinib

Substanzen

Heterocyclic Compounds, 3-RingPlacebosupadacitinib

Autor:innen und Institutionen

  • Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
  • Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka-shi, Tokyo, Japan.
  • Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuernberg, Erlangen, Germany.
  • Department of Gastroenterology, Dermatology, and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Gastroenterology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  • Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.

Förderung

  • AbbVie

Zitieren

APA

Colombel, J. F., Hisamatsu, T., Atreya, R., Bresso, F., Thin, L., Panaccione, R., Parra, R. S., Ford, S., Remple, V. P., Lacerda, A. P., Anyanwu, S. I., Mallick, M., Garrison, A., & Regueiro, M. (2024). Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy. Clinical Gastroenterology and Hepatology, 22(8), 1668-1677. https://doi.org/10.1016/j.cgh.2024.02.027

Vancouver

Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, et al. Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy. Clinical Gastroenterology and Hepatology. 2024;22(8):1668-1677. doi:10.1016/j.cgh.2024.02.027

BibTeX
@article{Colombel2024,
  author = {Colombel, Jean-Frédéric and Hisamatsu, Tadakazu and Atreya, Raja and Bresso, Francesca and Thin, Lena and Panaccione, Remo and Parra, Rogério Serafim and Ford, Sharanya and Remple, Valencia P and Lacerda, Ana Paula and Anyanwu, Samuel I and Mallick, Madhuja and Garrison, Andrew and Regueiro, Miguel},
  title = {Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {8},
  pages = {1668--1677},
  doi = {10.1016/j.cgh.2024.02.027}
}
Kostenlos starten →